Up­dat­ed: Even with no pri­ma­ry end­point da­ta, Tau­Rx still eyes Alzheimer’s fil­ing af­ter PhI­II up­date

De­spite its in­abil­i­ty to con­duct a Phase III pri­ma­ry analy­sis, Tau­Rx is plan­ning reg­u­la­to­ry fil­ings for its tau ag­gre­ga­tion in­hibitor in Alzheimer’s dis­ease af­ter re­port­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER